Long-term remissions of lymphoma after fever-inducing therapy with bacterial toxins have been documented since William Coley.[@R1] Primary cutaneous lymphomas make up about 5% of all non-Hodgkin\'s lymphoma (annual incidence, 1:100 000); 20% to 25% of these are primary cutaneous B-cell lymphomas (PCBCL).[@R2]^--^[@R4] The most common subtypes are primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), and diffuse large cell lymphoma. The follicle center and marginal zone B-cell lymphomas tend to be indolent and have a 5-year survival of more than 95%[@R5]; although relapses are common, systemic progression is rare. Single lesions are treated with radiotherapy, intralesional steroids, surgical excision, or a "wait and see" strategy. Multifocal or relapsed systemic disease is usually treated with rituximab (R, anti-CD20 monoclonal antibody), single- or multi-agent chemotherapy (eg, chlorambucil or cyclophosphamide; vincristine; prednisolone; cyclophosphamide, vincristine, and predisolone \[CVP\]), or immunotherapy with interferon-α.[@R6]^,^[@R7] PCBCL is associated with immune dysregulation and in some instances immunodeficiency with chronic inflammation (particularly PCMZL), eg, in rheumatoid arthritis or Sjügren\'s syndrome and with *Borrelia burgdorferi* infection.[@R8]^--^[@R12] They respond to immunological treatments like intralesional injections of interferon-α[@R13] or adenovirus-encoding interferon-γ, which can even lead to remission in non-injected distant lesions.[@R14] Survival in systemic lymphoma correlates with tumor-infiltrating immune cells,[@R15] and for the occasionally observed spontaneous regressions of non-Hodgkin\'s lymphoma, immunologic mechanisms have been proposed.[@R16]^,^[@R17]

Mistletoe extract (ME) is a whole plant remedy derived from *Viscum album* L, a hemi-parasitic shrub; it is widely used for complementary cancer treatment, especially in Europe, in conjunction with conventional therapy.[@R18] A variety of biologically active compounds have been isolated from ME, including mistletoe lec-tins (MLs), viscotoxins, oligo- and polysaccharides, and others.[@R19]^,^[@R20] ME has immunostimulatory activity (in vivo and in vitro activation of monocytes/macrophages, granulocytes, natural killer cells, T-cells, dendritic cells, induction of a variety of cytokines[@R19]^,^[@R20]), and several compounds (ML in particular) are cytotoxic with established apoptosis-inducing effects.[@R19]^--^[@R21]

ME is usually applied subcutaneously at a low starting dose, which is slowly titrated upwards and adjusted individually. This approach is associated with improvement of quality of life and probably also survival.[@R22]^--^[@R24] Tumor remission has rarely been observed with low dosages, but mainly after high, fever-inducing ME dosage, often injected intratumorally or as an intravenous (IV) infusion.[@R22]^--^[@R24] However, these observations have been reported only in case series and case reports.[@R23]^--^[@R27] No randomized trials have yet investigated the role of ME in the treatment of lymphoma. Apart from dose-dependent flu-like symptoms, fever, and inflammatory reactions at the injected sites, ME treatment is safe. Occasionally, hyper-sensitivity reactions are reported.[@R28]

Two patients with primary cutaneous lymphoma were treated at the Park Attwood Clinic (PAC, which closed in 2010), a British center specializing in complementary cancer care and particularly in high-dose and fever-inducing ME treatment. Informed consent for ME treatment was obtained from both patients with the understanding that this would not replace recommended therapies and there was good evidence that ME could improve tolerance of mainstream treatment when applied concurrently.

CASE 1: PRIMARY CUTANEOUS FOLLICLE CENTER B-CELL LYMPHOMA
=========================================================

A 51-year-old female presented with 2 lesions on the left lower leg in May 2008 at the oncology department of a large tertiary hospital (Aberdeen Royal Infirmary \[ARI\]). She had first noticed in the summer of 2007 a lesion in the left upper Achilles region, which increased in size and became red. In autumn 2007, a similar lesion developed over the mid shin of the same leg, and in the weeks leading up to presentation, a couple of much smaller satellite lesions appeared around the anterior lesion.

Histopathology confirmed grade 1 follicular B-cell lymphoma ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). Staging computed tomography (CT) scan (chest, abdomen, pelvis) reported no intraabdominal or pelvic lymphadenopathy but showed one 2.7 × 1.7 inguinal lymph node, which was not biopsied. Stage was pT~2b~cN~x~M~0.~[@R26] Hematology, biochemistry, and trephine bone marrow biopsy were essentially normal. IgH gene rearrangement analysis found clonality, confirming B-cell lymphoma; T-cell receptor (TCR)-β--ve; TCR-γ very weakly polyclonal. Cytogenetics: t(11;14) and t(14;18) translocations were not tested.

![Cellular lymphoid tumor. The pattern is largely diffuse with focal nodular areas (H&E ×10). *Image courtesy of Dr Ghada Bashat, Pathology, Aberdeen Royal Infirmary.*](gahmj.1.1.006.g001){#F1}

![Cellular lymphoid tumor. The pattern is largely diffuse with focal nodular areas (H&E ×20). *Image courtesy of Dr Ghada Bashat, Pathology, Aberdeen Royal Infirmary*.](gahmj.1.1.006.g002){#F2}

The patient was generally well; she had no history of injury or infection and no B symptoms, such as fatigue, night sweats, weight loss, or pruritus. She had longstanding assumptive skin lipomas in different areas of the body but had been generally healthy, had a grown daughter, worked as a movement therapist, was a non-smoker, drank no alcohol, took no regular medications, and reported no allergies.

In view of the multicentric lesions, with satellites and possible regional node involvement indicative of advancement, it was recommended she undergo systemic immuno-chemotherapy with 6 cycles of cyclophosphamide, vincristine, and prednisone plus rituximab (R-CVP) and involved-field radiotherapy on completion of the cycles. Although the patient was not opposed to this treatment in principle, she decided to keep it in reserve and improve her immunity with ME treatment first.

On presentation for ME treatment in June 2008, the patient had a posterior lesion in the left proximal Achilles region measuring 5 cm × 4 cm ([Figure 3](#F3){ref-type="fig"}) and an anterior mid shin tumor measuring 4 cm × 2 cm ([Figure 4](#F4){ref-type="fig"}), with a number of surrounding satellites, each \< 1.5 cm. The 2 large lesions were raised, red, and warm to the touch. The overlying skin was thinned but intact. There were no signs of deep tissue infiltration; she reported no pain, and no neurological deficits were ascertained. The left leg was well perfused, but there was pitting edema around the lesions and the ankle.

![Primary cutaneous B-cell lymphoma in July 2008. Posterior lesion left lower leg.](gahmj.1.1.006.g003){#F3}

![Primary cutaneous B-cell lymphoma in July 2008. Anterior lesion left lower leg; surrounding satellites not showing clearly.](gahmj.1.1.006.g004){#F4}

Treatment
---------

Treatment with ME (using *Abnobaviscum fraxini*) comprised a combination of IV, intratumoral (IT), and subcutaneous (SC) applications over 12.3 months and IV and SC application over another 8 months. Details are shown in [Table 1](#T1){ref-type="table"}. Treatment was subdivided in an induction phase, wherein febrile reactions to ME are elicited, and a postinduction phase. ME treatment was combined with whole-body hyperthermia (WBHT)---a technique to increase core temperature to 39° to 39.5°C for 2 to 5 hours with water-filtered infrared A radiation under controlled conditions. The skin lesions were not directly targeted. She had no other cancer treatments and was not taking any medications.

###### 

Treatment Schedule (06/02/08--06/08/09) of Patient With PCBCL[^a^](#TF1-1){ref-type="table-fn"}

  Month                  Day or Interval                            ME Dosage (mg) Per Application                                            WBHT                                                
  ---------------------- ------------------------------------------ ------------------------------------------------------------------------- --------------------------------------- ----------- --------
  Induction phase                                                                                                                                                                                 
  0                      1                                          40                                                                        ---                                     ---         
                         2                                          80                                                                        ---                                     1           
                         3                                          160                                                                       1                                       10          
                         4                                          ---                                                                       4                                       20          
                         8                                          160                                                                       10                                      30          
                         11                                         160                                                                       20                                      20          
                         15                                         160                                                                       ---                                     40          
  Post-induction phase                                                                                                                                                                            
                         16                                         ---                                                                       40                                      40          
                         18                                         160                                                                       ---                                     ---         
                         21--28[^c^](#TF1-3){ref-type="table-fn"}   ---                                                                       ---                                     (3 ×) 40    
                         25                                         200                                                                       ---                                     ---         
  1                      29--35                                     ---                                                                       ---                                     (2 ×) 40    
                         32                                         200                                                                       ---                                     ---         
                         36--42                                     ---                                                                       ---                                     40          
                         36                                         200                                                                       80                                      ---         
                         37                                         ---                                                                       40                                      ---         No. 1
                         42                                         200                                                                       120                                     ---         No. 2
                         43--49                                     ---                                                                       ---                                     (2 ×) 40    
                         46                                         200                                                                       ---                                     ---         
                         50--56                                     ---                                                                       ---                                     (2 ×) 40    
                         53                                         200                                                                       ---                                     80          
  2                      57                                         ---                                                                       240[^d^](#TF1-4){ref-type="table-fn"}   ---         
                         58                                         200                                                                       ---                                     ---         No. 3
                         61                                         ---                                                                       ---                                     ---         
                         64--70                                     ---                                                                       ---                                     (2 ×) 40    
                         67                                         200                                                                       320[^d^](#TF1-4){ref-type="table-fn"}   ---         
                         71--77                                     ---                                                                       ---                                     (2 ×) 40    
                         74                                         200                                                                       ---                                     ---         
                         78                                         ---                                                                       320[^d^](#TF1-4){ref-type="table-fn"}   40          
                         79                                         200                                                                       ---                                     ---         No. 4
  3                      85--91                                     ---                                                                       ---                                     40          
                         88                                         200                                                                       320[^d^](#TF1-4){ref-type="table-fn"}   ---         
                         92--98                                     ---                                                                       ---                                     (2 ×) 40    
                         95                                         200                                                                       ---                                     ---         
                         99                                         ---                                                                       320[^d^](#TF1-4){ref-type="table-fn"}   ---         
                         100                                        200                                                                       ---                                     ---         No. 5
                         103--112                                   ---                                                                       ---                                     (2 ×) 40    
                         109                                        200                                                                       ---                                     ---         
                         113--119                                   ---                                                                       ---                                     (2 ×) 40    
                         116                                        200                                                                       ---                                     ---         
  4                      120                                        ---                                                                       320[^d^](#TF1-4){ref-type="table-fn"}   20          
                         127--140                                   ---                                                                       ---                                     (4 ×) 40    
                         135                                        200                                                                       ---                                     ---         No. 7
  5                      141--161                                   ---                                                                       ---                                     (5 ×) 40    
                         162                                        ---                                                                       360[^d^](#TF1-4){ref-type="table-fn"}   ---         
                         163                                        200                                                                       ---                                     ---         No. 8
  6                      169--182                                   ---                                                                       ---                                     (3 ×) 40    
                         178                                        200                                                                       ---                                     ---         
                         183--189                                   ---                                                                       ---                                     (2 ×) 40    
                         190                                        ---                                                                       400[^d^](#TF1-4){ref-type="table-fn"}   ---         
                         191                                        200                                                                       ---                                     ---         No. 9
                         197--210                                   ---                                                                       ---                                     (4 ×) 40    
                         204                                        200                                                                       ---                                     ---         
                         211--231                                   ---                                                                       ---                                     (6 ×) 40    
                         233                                        ---                                                                       400[^d^](#TF1-4){ref-type="table-fn"}   ---         
                         234                                        200                                                                       ---                                     ---         No. 10
                         237--271                                   ---                                                                       ---                                     (12 ×) 20   
                         254                                        200                                                                       ---                                     ---         
                         272                                        ---                                                                       400[^d^](#TF1-4){ref-type="table-fn"}   ---         
                         279--369                                   ---                                                                       ---                                     (13 ×) 40   
                         338                                        200                                                                       ---                                     ---         
  12                     370                                        ---                                                                       240[^d^](#TF1-4){ref-type="table-fn"}   ---         
                         371                                        200                                                                       ---                                     ---         No. 12
                         372                                        End of IT treatment; subsequent IV and SC treatment and WBHT not shown.                                                       
  **Total**                                                                                                                                                                                       
  No. of applications                                               33                                                                        19                                      81          12 ×
  ME dosage                                                         6120                                                                      3950                                    2901        

Abbreviations: IT, intratumoral; IV, intravenous; ME, mistletoe extract; PCBCL, primary cutaneous B-cell lymphoma; SC, subcutaneous; WBHT, whole-body hyperthermia.

Month and day (interval) of treatment; mode, dose, and number of ME applications; application of WBHT.

Infused in 250 mL sodium chloride 0.9%, over 60--90 minutes.

Treatment periods of 1 or more weeks during which SC injections were given.

IT distributed over both lesions.

During induction, the patient had 4 febrile responses of ≥38.5°C lasting \< 24 hours with maximum readings of 38.5°C (after day 3); 38.7°C (after day 4); 39.1°C (after day 8); and 38.6°C (after day 11). For the IT approach, the lesions were injected from the healthy skin margins to avoid breaking the paper-thin skin overlying the bulging tumors. The volume of ME fluid often exceeded 20 mL (20 mg/mL/ampoule) and was injected evenly intraand perilesional while repositioning the needle during injection.

After IT treatment, the lesions responded with immediate postinjection swelling and inflammation, followed by clinical resolution of inflammation, and over the course of treatment, the lesions successively appeared less inflamed. The rate of regression seemed slightly accelerated after starting WBHT (day 37), and after 4 months, there was a clear overall improvement. The lesions continued to show injection-associated fluctuations, and the posterior lesion resolved first.

The lesions steadily decreased in volume, consistency, and redness. The remission was assessed by visual inspection and palpation and confirmed by 3 independent clinicians from 3 different clinical settings, including the ARI. The overall fitness and stamina of the patient improved. Re-scanning in May 2009 reflected "No significant supraclavicular, axillary or mediastinal ... retroperitoneal or pelvic lymphadenopathy; as before, there are inguinal nodes the largest of which is on the left and measuring 1.3 × 1.8 cm. This node was documented as 2.7 × 1.7 cm on staging." Routine full blood count and biochemistry were normal. Given the favorable clinical signs of control, the IT injections were discontinued at 12.3 months. Combined IV and SC ME treatment with WBHT continued for another 8 months, and the lesions continued to regress. The areas blanched eventually, leaving depressed (posterior, [Figure 5](#F5){ref-type="fig"}) and level (anterior lesion, [Figure 6](#F6){ref-type="fig"}) hyperpigmented areas. Conventional therapy was deferred indefinitely. At last review in December 2011, the patient was doing well and remained in remission; the appearances were similar to those from June 2011 ([Figures 7](#F7){ref-type="fig"} and [8](#F8){ref-type="fig"}).

![Primary cutaneous B-cell lymphoma in May 2010. Posterior left lower leg; posttreatment pigmentation and depression.](gahmj.1.1.006.g005){#F5}

![Primary cutaneous B-cell lymphoma in May 2010. Anterior left lower leg showing pigmentation changes.](gahmj.1.1.006.g006){#F6}

![Primary cutaneous B-cell lymphoma in June 2011. Posterior left lower leg.](gahmj.1.1.006.g007){#F7}

![Primary cutaneous B-cell lymphoma in June 2011. Anterior left lower leg.](gahmj.1.1.006.g008){#F8}

Tolerability
------------

Fever was associated with sickness (grade 1) and grade 2 to 3 fatigue. The subsequent combined IV/IT administrations elicited fatigue (grade 1--2) for 1 to 3 days. No hypersensitivity was observed. SC injections elicited site responses of 4 cm to 5 cm erythema for \< 2 days. The intralesional injections with concentrated ME were uncomfortable, with fluid pressure and pain for a few minutes, but did not require analgesia. Inflammatory responses (erythema, swelling, tenderness) and (transient) increase of edema of the lower leg lasted for \< 2 days and were treated with cooling applications. The patient had no phlebitis at cannulation sites.

Patient\'s Description of Treatment
-----------------------------------

The patient in this case described the treatment experience as follows:

> With the initial fevers and fluctuating energy levels, my treatment was intense, exhausting and it was the only thing I could do during that time: but not a burden and a meaningful experience. During one of the high fevers an old traumatic experience became disentangled and I have felt freed up since; I now feel better than before my cancer, physically and emotionally. I also felt empowered by the working together with my doctors to develop the best treatment for me. I am very grateful for my new health!

CASE 2: PRIMARY CUTANEOUS MARGINAL ZONE B-CELL LYMPHOMA
=======================================================

A 52-year-old flight attendant was diagnosed at the same oncology department (ARI) with stage 2A, pT~2a~c-N~x~M~0~ primary cutaneous marginal zone B-cell lymphoma (PCMZL). In December 2007, 2 to 3 days after venapunction, he developed a lesion in the left antecubital fossa, which was excised in May 2008. The histopathology showed nodal marginal zone lymphoma ([Figure 9](#F9){ref-type="fig"}). A staging CT scan of the neck, chest, abdomen, and pelvis showed no signs of systemic disease; trephine bone marrow biopsy, biochemistry, and hematology were normal. Shortly after excision, the patient developed a second lesion on the right anterior chest wall, medial to the right anterior axillary fold. The lesion was only palpable (no photographs). The patient was asymptomatic, had no recent weight loss or fatigue. Several treatment options were recommended: R-CVP, 10 fractions of involved-field radiotherapy of the 2 sites, or 6 months\' pulsed chlorambucil; he declined these options.

![Nodular marginal zone lymphoma. The architecture of the node is diffusely effaced by a population of lymphoid, plasmacytic, and histiocytic cells (H&E ×10). *Image courtesy of Dr Ghada Bashat, Pathology, Aberdeen Royal Infirmary.*](gahmj.1.1.006.g009){#F9}

The patient had a history of rosacea with keratitis; actinic keratoses of upper back (treated with occasional cryotherapy); 2 basal cell carcinomas---one of the upper back (excised 1999) and one of the left leg (excised early 2007)---and an uncertain diagnosis of facial cutaneous scleroderma with no visceral involvement, but raised titres of antinuclear factor, which was unresponsive to azathioprine and oral prednisolone (2004). He used nicotine and alcohol moderately. Apart from emollients, he used no other regular conventional medications, reported no formal allergies, and was mistletoe-naïve. He had had no recent infections and no soft tissue trauma.

On presentation at PAC in August 2008, the patient was in good general health, with a Karnofsky Performance Scale status of \> 90%. There was one soft and mobile lymph node in the left axilla. The right upper thoracic lesion was 2 × 3 cm palpable and mobile. There were no other abnormal findings.

Treatment
---------

Combined IV, IT, and SC treatment with ME (*Abnobaviscum fraxini*) was provided over a period of 8.5 months. Details are shown in [Table 2](#T2){ref-type="table"}. During informed consent, it was explained to the patient that his underlying autoimmune condition theoretically could be aggravated. He received no other anticancer treatments.

###### 

Treatment Schedule (08/09/08--04/20/09) and Tumor Size of Patient With PCMZL[^a^](#TF2-1){ref-type="table-fn"}

  Month                  Day or Interval   ME Dosage (mg) Per Application                                   Tumor Size (cm) Palpation               
  ---------------------- ----------------- ---------------------------------------------------------------- --------------------------- ----------- -----------------
  Induction phase                                                                                                                                   
  0                      1                 40                                                               ---                         ---         3 × 2
                         2                 80                                                               ---                         0.2         
                         3                 160                                                              ---                         ---         
                         4                 200                                                              2                           0.2         
                         5                 ---                                                              10                          ---         
                         7                 200                                                              20                          ---         
                         10                200                                                              40                          2           
                         13                200                                                              80                          4           
  Post-induction phase                                                                                                                              
                         22                ---                                                              ---                         12          
  1                      26--47            ---                                                              ---                         (7 ×) 20    5 × 4
                         52                100                                                              40                          ---         
  2                      54--64            ---                                                              ---                         (3 ×) 20    
                         66                140                                                              40                          ---         
                         71--85            ---                                                              ---                         (5 ×) 20    
  3                      87                120                                                              40                          ---         
                         93--107           ---                                                              ---                         (4 ×) 20    
                         109               160                                                              40                          ---         
  4                      114--128          ---                                                              ---                         (5 ×) 20    
                         130               180                                                              100                         ---         
                         132--149          ---                                                              ---                         (6 ×) 20    
  5                      151               180                                                              100                         ---         
                         153--170          ---                                                              ---                         (6 ×) 20    
                         172               200                                                              100                         ---         Reducing
  6                      176--191          ---                                                              ---                         (5 ×) 20    
                         193               160                                                              80                          ---         
  7                      195--219          ---                                                              ---                         (8 ×) 20    
                         221               160                                                              80                          ---         0.5 × 0.5 × 0.3
                         223--254          ---                                                              ---                         (10 ×) 20   
  8                      256               160                                                              20                          ---         Impalpable
                         257               End of IT treatment; subsequent IV and SC treatment not shown.   CR                                      
  **Total**                                                                                                                                         
  No. of applications                      17 ×                                                             15 ×                        64 ×        
  ME dose                                  2 640                                                            792                         1 198.4     

Abbreviations: CR, complete response; IT, intratumoral; IV, intravenous; ME, mistletoe extract; PCMZL, primary cutaneous marginal zone lymphoma; SC, subcutaneous.

Month and day (interval) of treatment; mode, dose, and number of ME applications.

Infused in 250 mL sodium chloride 0.9% over 60--90 minutes.

He had 6 febrile responses (38° to 39.2°C) between days 5 and 87. There were no signs of concomitant infection. After IT injections, the lymphoma lesion each time showed a similar response pattern of inflammatory swelling and erythema for up to 2 days, then resolution. The lesion increased in size over the first month to 4 × 5 cm, then remained unchanged for 3 months, and after the IT dose was increased to 100 mg ME, the lesion steadily diminished to become impalpable at 8.5 months ([Table 2](#T2){ref-type="table"}). This complete response (CR) was clinically verified by 3 clinicians in 2 separate institutions, including the ARI. The ITs were ceased in April 2009, and SC and IV treatment was continued until November 2010. A CT scan in March 2010 was unre-markable. The patient was last reviewed in December 2011 and was doing well and in remission; no new lesions had developed.

Tolerability
------------

During the first 3 months, treatment was challenging. The fever episodes in particular were accompanied by sickness and grade 1 to 2 fatigue. Once, grade 2 phlebitis developed at an IV cannulation site and resolved spontaneously; interestingly, no local relapse resulted from this. The SC and IT doses were followed by typical inflammatory site reactions that resolved without scarring or subcutaneous fibrosis. No hypersensitivity and no signs or symptoms of autoimmune reactivation were observed. After 6 months, the patient consistently reported improved vitality and well-being.

Patient\'s Description of Treatment
-----------------------------------

The patient in this case described the treatment experience as follows:

> *When I was offered chemo-/radiotherapy, this seemed aggressive to me like a sledge hammer* \[sic\] *to crack a nut. My understanding of mistletoe therapy felt gentler and simply like the right thing to do. The treatment itself, whilst challenging, confirmed my feeling that it was the bedrock, the main stay* \[sic\] *of being healed.*

DISCUSSION
==========

The primary cutaneous B-cell lymphoma of 2 patients regressed after administration of a combination of SC, IV, and IT applications of high-dose, fever-inducing ME treatment. The rationale for the combination was to optimize immune responses as currently understood to elicit fever and to apply the principle of "in situ" vaccination with IT application. In one patient, WBHT was added to draw on the benefits of improved immune competence that is associated with fever-range hyperthermia.[@R29] Three and a half years since commencement, the patients remain in clinical remission.

With high dosage, especially local ME applications, tumor remissions have been reported repeatedly in a number of tumor types, including breast cancer, Merkel cell cancer, primary liver cancer, pancreatic cancer, and cutaneous squamous cell cancer.[@R25]^--^[@R27] Still, high-dose and combined IT, IV, and SC administration that aims to elicit febrile induction is uncommon and underreported.

The literature on ME treatment of lymphoma is limited compared to that of other tumor types. One retrospective study describes favorable outcomes, including a few remissions in a group of 61 patients with follicular non-Hodgkin\'s lymphoma treated with a lowlectin ME (Iscador Pini) either alone or combined with or on completion of chemotherapy.[@R30] Another retrospective study primarily investigated safety aspects of ME treatment in Hodgkin\'s and non-Hodgkin\'s lymphoma and found no risks.[@R31] Some case reports describe remission of non-Hodgkin\'s lymphoma under ME monotherapy,[@R32]^--^[@R35] including 2 in cutaneous T-cell lymphoma in children.[@R36]^,^[@R37] In these cases, the dosage was lower than in the cases reported here and applied mainly subcutaneously and only partly intravenously and intratumorally. At least one fever reaction was reported.

Preclinical studies with lymphoma cells and murine lymphoma models treated with ME, isolated MLs, recombinant ML, and other ME peptides have consistently shown antitumoral effects with tumor inhibition, inhibition of metastases, and survival benefit.[@R19]^,^[@R38]^--^[@R42] ME contain several cytotoxic ingredients, among them lectins and viscotoxins, which are particularly abundant in *Abnobaviscum fraxini*. When lec-tins are applied systemically, their cytotoxicity is moderated by serum proteins[@R43] and later by the occur-rence of anti-ML antibodies;[@R44] hence, their cytotoxicity is to be expected, primarily with IT administration. However, a disease response could also be effected by an immunological mechanism, as has been demonstrated for ME repeatedly.[@R19]^,^[@R20] Furthermore, fever seems to have a role in tumor defense.[@R45] The impact of ME treatment cannot be easily ascertained when used concurrently with mainstream cancer therapy. Occasionally, however, patients postpone or decline recommended conventional treatment in favor of ME, and such cases allow evaluation of ME treatment alone. Two of these patients are described above; these are the only two cutaneous lymphoma cases treated at PAC with ME alone and are therefore unselected. The cases of 2 other patients from PAC who had cancer at other sites and were treated with ME monotherapy have been published previously.[@R27]

In lymphoma, spontaneous remission is estimated to occur in 5% to 20% of cases. It is sometimes of long duration[@R16]^,^[@R17]^,^[@R46]^,^[@R47] and often is associated with reducing an immunosuppressive treatment or condition; following fever, viral or bacterial infections, or vaccination; or after biopsy and following eradication of helicobacter in gastric lymphoma.[@R17] In a small follow-up study observing patients over many years, spontaneous remissions were reported in 4 of 16 patients with PCFCL (one of them complete) and in 4 of 8 patients with PCMZL (none of them complete), all of whom had a relapse.[@R48] Although spontaneous remission could have played a role in the cases presented here, in the first of the cases presented, the lesions had grown progressively until commencement of ME treatment and then steadily decreased, with fluctuating treatment-related inflammatory responses. In the second case, the lesion resolved after initial treatment-related increase and with some delay, which is a known response pattern in ME-associated tumor remissions.[@R26]^,^[@R30] Therefore, a mere coincidence is unlikely, especially as the 2 cases are unselected (meaning that they were not selected from a larger group of patients with cutaneous lymphomas treated with ME but were the only patients with cutaneous lymphonas treated in this way) and represent the only patients with PCBCL from PAC that had been treated with ME monotherapy. One also has to consider that the fever-induction ME treatment is likely to upregulate just those mechanisms implicated in the frequent spontaneous remission described for lymphoma.

Two further case publications on ME treatment of a related entity, CD30+ T-cell lympho-proliferation, reported complete regression of multiple and active cutaneous and nodal disease.[@R37]^,^[@R38] In one case, treatment consisted of low-dose IV (3 infusions of 0.02 mg, 0.2 mg, and 2 mg) and SC (up to 2 mg twice a week) without fever or site responses, with a noticeable disease response within 1 week and durable (30 months) complete response (CR) within 4 weeks. The second case was treated with primary fever intent (38°C), IT, and SC, and had a dose-dependent partial response and CR that relapsed with a lower-dose ME but regressed again with dose increase.

A differentiated appreciation of the singular components of the combined ME treatment---the specific role of fever and each of the specific contributions of SC, IT, and IV---and of the synergies is not possible given the current knowledge and require further research.

Although treatment was well tolerated and the safety observed is in accordance with other investigations on the safety of ME treatment in higher dosage,[@R28] this treatment should be reserved for use by physicians who have experience with ME application in higher dosages and IT/IV until further investigations have explored the role of high-dose, fever-inducing ME in cancer and its safety in more detail.

CONCLUSION
==========

High-dose, fever-inducing mistletoe treatment seems to have beneficial effects in two cases of primary cutaneous B-cell lymphoma. Further research is needed to investigate antitumor effects, potential mechanisms of action, best mode of application, and the associated safety and efficacy.

Consent
-------

Written informed consent was obtained from both patients for publication of the report and the accompanying Figures. They both read the final version of the paper and confirmed its contents.
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